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Abstract
Purine nucleoside phosphorylase had previously been engineered to accept 6-amino substituted purine nucleosides by two active site
substitutions, Asn243Asp; Lys244Gln. In the present study, recombinant adenosine phosphorylase (AP) has been conjugated to branched
polyethylene glycol (PEG) polymers of approximately 42.5 kDa. Matrix-assisted laser desorption/ionization analysis and SDS acrylamide
electrophoresis analysis indicated a subunit composition of greater than 205 kDa consistent with the conjugation of as many as four PEG
molecules per AP subunit. The PEG-conjugated enzyme retained greater than 90% of the native catalytic activity. Administration of the
enzyme to mice demonstrated the PEG–AP to have a 67-fold increased plasma half-life compared to the native enzyme, 65.1F 2.9 h versus
57.8F 1.1 min, respectively. PEG–AP was principally confined to the plasma with minimal activity detected in tissues and of these spleen
had the greatest activity and essentially no activity was found in urine. PEG–AP has retained activity with inosine and its injection into PNP-
deficient mice resulted in a 2.7-fold increase in urine urate. AP was also shown to protect human CEM cells in culture from the toxic effects
of 2V-deoxyadenosine. These studies provide evidence for consideration of PEG–AP as an alternative enzyme therapy for the inherited
deficiency of adenosine deaminase.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Proteins conjugated to polyethylene glycol (PEG) have
been developed for a variety of therapeutic applications.
PEG-conjugated enzymes are retained in plasma and in
general require their target substrates and products to be
transportable across cell membranes and to have activity
independent of cofactors. We propose a genetically engi-
neered adenosine phosphorylase (AP) [1] to have applica-
tion as an alternate approach to enzyme therapy for
adenosine deaminase (ADA) deficiency as well as a novel
metabolic route for the activation of nucleoside analog
prodrugs. PEG-conjugated ADA [2,3] is an effective agent
in the treatment of ADA deficiency. Antibodies to the
bovine PEG–enzyme have in some instances developed
posing further management complications [4] and extreme
thrombocytosis in response to PEG–ADA has also been
encountered [5]. The capability of engineered AP to cleave
2V-deoxyadenosine suggests the possibility of an alternate
enzymatic approach to the treatment of ADA deficiency.
The broad specificity of the bacterial purine nucleoside
phosphorylase has also been exploited in activating nucleo-
side analogs by conversion to their respective base where
they might be converted to toxic nucleotides via phosphor-
ibosyltransferase activity [6,7]. AP may share the potential
to convert nucleoside analogs to their respective purine base
prodrug form.
Purine nucleoside phosphorylase reversibly catalyzes the
phosphorolytic cleavage of purine nucleosides to their
respective purine base and ribose-phosphate. The bacterial
purine nucleoside phosphorylase accepts variability at the
C6 position of the purine base and the purine nucleo-bases
containing hypoxanthine, guanine or adenine are all accep-
ted as substrates [8,9]. Nucleoside phosphorylases with
specificity for adenosine have been recognized [10]. The
recent cloning and characterization of protozoan purine
nucleoside phosphorylases reveals that from Trichonomas
vaginalis [11] to be a homologue of the bacterial enzyme
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with capability of cleaving nucleosides containing the pu-
rine bases adenine, hypoxanthine or guanine. That from
Plasmodium falciparum more closely resembles the mam-
malian enzyme and does not accept adenosine [12]. Mam-
malian purine nucleoside phosphorylase has restricted
specificity and accepts inosine and guanosine as substrates
but has effectively no activity with adenosine. We have by
site-directed mutagenesis altered two residues in the active
site of the mammalian enzyme, Asn243Asp and Lys244Gln,
to alter its specificity such that adenosine is preferentially
accepted as substrate [1]. The present study explores the
development of PEG-conjugated AP and its in vivo proper-
ties in the PNP-deficient mouse model [13].
In the present study, we explore the production and in
vivo characteristics of PEG-conjugated AP in assessing its
potential as an alternate form of enzyme therapy for ADA
deficiency or for the activation of prodrug forms of adeno-
sine analogs.
2. Materials and methods
2.1. Materials
The histidine tag expression vector pET28a-c(+) was
from Novagen (Madison, WI) and Ni-NTA Superflow resin
from Qiagen Inc. Canada (Mississauga, Ontario). Chemicals
including 2-chloro-2V-deoxyadenosine and 2V-deoxyadeno-
sine were from Sigma (Oakville, ON) except for 2-chlor-
oadenine, Biolog Life Science Institute (Bremen, Germany),
and 2,4,6-tribromo-3-hydroxybenzoic acid, Boehringer-
Mannheim (UK). Sodium heparin, 1000 USP units/ml,
was from Organon (Toronto, Canada). The N-hydroxysuc-
cinimide ester of branched methoxypolyethylene glycol of
approximately 42.5 kDa (mPEG2-NHS 40K) was purchased
from Shearwater Polymers Inc. (Huntsville, AL). SDS-
PAGE reagents and protein MW markers were purchased
from Bio-Rad Laboratories (Hercules, CA).
2.2. Production and purification of AP
The histidine tag expression vector pET28a-c(+) (Nova-
gen) was modified by removing a 5Vregion between NdeI
and BamH1 to reduce the number of amino acids in the N-
terminal tag. The coding sequence for AP was excised with
EcoRI and HindIII from the previous pMAL-C2 construct
[1], and inserted into the multiple cloning site of pET28a-
c(+). The plasmid was transformed into a T7 expression
strain BL21(DE3)pLysS and positively identified by growth
on kanamycin-containing media. The resulting construct
codes for 24 additional N-terminal amino acids including
the 6-histidine tag, MGSSHHHHHHSSGLVPRGSHRSEF,
and has a molecular mass of 34,979 Da.
Cells containing the plasmid were induced with 0.3 mM
IPTG for 2 h in LB broth containing 35 Ag/ml kanamycin,
harvested and lysed by French press (SLM instruments) in
50 mM sodium phosphate, 300 mM NaCl, 10 mM imida-
zole, and 10 mM h-mercaptoethanol, pH 8.0. After centri-
fugation, 9000 g, for 30 min, the crude supernatant was
passed over a column packed with 7 ml Ni-NTA Superflow
resin at a rate of 1 ml/min. The column was washed with
step gradients at 1–2 ml/min of the same buffer containing
increasing imidazole from 10, 20, 40 to 100 mM. AP was
eluted at 200 mM imidazole and stored as stock in 50%
glycerol at 4 jC. Purification steps were monitored with
12% SDS-PAGE. Protein to be used for native AP injections
was transferred to 154 mM NaCl, 2 mM sodium phosphate,
22% glycerol, pH 7.4, and stored at 4 jC.
2.3. PEG conjugation of AP
PEG conjugation reactions were based on recommenda-
tions from the supplier (Shearwater Polymers) and modified
from a protocol previously reported [14]. Initial reactions
were carried out at molar ratios of PEG to protein between
10:1 and 160:1 to determine optimal conjugation conditions
and monitored on SDS-PAGE. The ratio of 100:1 was then
used for all subsequent reactions. AP was transferred to 20
mM sodium phosphate, pH 8.25 using a PD-10 desalting
column (Amersham Biosciences, Uppsala, Sweden). The
mPEG2-NHS 40K reagent, typically 57 mg, was rapidly
dissolved by vortexing in 20 mM sodium phosphate, pH
8.25, and then immediately mixed with the AP, 1 mg. After
15 min, an additional 57 mg of mPEG2-NHS 40K was
added. The reaction was carried out under nitrogen in the
dark at 21 jC for 1.25 h and stopped by adding 1/10 volume
of 1 M sodium phosphate, pH 6.5, on ice and stored at 4 jC
before further processing.
2.4. Purification and analysis of PEG–AP
Unreacted PEG and contaminants were separated from
PEG–AP on a Superdex 200 HR 10/30 size-exclusion
column (Amersham) using a Pharmacia FPLC system.
Reaction products were eluted with 154 mM NaCl, 2 mM
sodium phosphate, pH 7.4, at a flow rate of 25 ml/h, the
eluate being monitored at 254 and 280 nm. The excluded
fractions containing PEG–AP were pooled and concen-
trated using an Amicon 8010 stirred ultrafiltration cell
equipped with a YM-10 membrane. PEG reaction products
were analyzed on 8% SDS gel and stored at 4 jC.
2.5. Matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry
Samples of PEG–AP and the native protein were pre-
pared in water using a PD-10 desalting column and con-
centrated by vacuum to greater than 0.5 mg/ml. Samples
were analyzed using a PerSeptive Biosystems Voyager-DE
STR mass spectrometer (Southern Alberta Mass Spectrom-
etry Centre, University of Calgary). Ions were differentiated
according to m/z using time-of-flight analysis [15,16].
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2.6. Enzyme activity assays
Enzyme activity was measured in a real-time spectro-
photometric assay by following the conversion of 2-chloro-
2V-deoxyadenosine to 2-chloroadenine. This novel substrate
was useful in that we have shown by HPLC that it is not a
substrate for PNP and is known to be resistant to deami-
nation by ADA [17,18] thus simplifying the assay to
measure only AP activity. Assays were performed in 35
mM sodium phosphate, pH 6.5, at 37 jC containing 1 mM
2-chloro-2V-deoxyadenosine in a coupled reaction with 1
mM 2,4,6-tribromo-3-hydroxybenzoic acid, 0.1 mM 4-
amino-antipyrene, xanthine oxidase 0.05 unit/ml, and per-
oxidase 0.002 unit/ml and followed at 512 nm as previously
described [1,19].
2.7. Native AP and PEG–AP administration in the purine
nucleoside phosphorylase-deficient mouse
Mice bearing a PNP point mutation which has been
backcrossed 12 generations on the C57BL/6J background,
B6-NPG, were used in these studies [13]. Native and PEG–
AP were filter sterilized, 0.2 Am (Gelman) and a bolus of 3.5
Ag protein/g body weight, was injected at time zero into the
peritoneal cavity of each mouse. At each time point, ap-
proximately 100 Al of blood was collected from the orbital
sinus into tubes containing 1 Al heparin (stock, 1000 USP/
ml) from each of three mice. Plasma was prepared by
centrifugation, treated with activated charcoal to remove
nucleosides and bases [20], clarified by centrifugation and
stored at 4 jC before assay. Either 30 or 5 Al plasma was
required for assay of native or PEG–AP-treated mice.
2.8. Urate analysis in urine
Urine samples were pooled from mice injected with
PEG–AP at 22, 34, 46, 58, 94, 118, 142 and 154 h,
respectively. The urine was deproteinized and neutralized
as described [21] and stored at  60 jC until analysis. Urine
components were separated on a reverse-phase Symmetry
C-18 column, 4.6 150 mm (Waters), using a Thermal
Separation Products SpectraSystem chromatograph equip-
ped with a spectrafocus detector set between 220 and 320
nm. Urate levels were monitored at 285 nm.
2.9. Tissue distribution of PEG–AP in the mouse
At 142 h after PEG–AP injection, mice were sacrificed
and the brain, liver, lung, kidney, spleen and thymus were
removed and stored at  60 jC. Tissues and urine was also
obtained from untreated B6-NPG control mice. Tissues were
weighed and homogenized in 1 ml of 40 mM sodium
phosphate, pH 6.5, with a Polytron (Brinkman Instruments)
and centrifuged at 14000 g for 25 min. The supernatant
was removed and exposed to activated charcoal and clari-
fied by centrifugation. Urine was also processed from pools
collected at 2, 5, 46, 94 and 154 h in a similar manner.
Samples were assayed for AP as described.
2.10. Lymphoblast culture and proliferation assay
The human lymphoblast CEM cell line, Southern Alberta
Cancer Research Centre Cell Bank (Calgary, Alberta), was
cultured in RPMI-1640 with 2 mM L-glutamine, 1 mM
sodium pyruvate and 10% heat-treated fetal bovine serum
from Gibco BRL (Burlington, Ontario). EHNA, an ADA
inhibitor, was added at 5 10 6 M [22]. All reagents were
sterilized by 0.2 Am filtration. Cell counts were obtained
with a Coulter Counter model Zf1.
3. Results and discussion
3.1. Production and characterization of PEG-conjugated
AP
PEG-conjugated proteins have been developed to im-
prove solubility, reduce immunogenicity and minimize in
vivo clearance mechanisms, thereby enhancing the circulat-
ing lifetime [23,24]. Plasma half-life gains for PEG-con-
jugated proteins have been reported to vary from 2 to greater
than 400-fold [14,25]. Engineering-increased numbers of
sites for attachment of PEG has been explored with bacterial
purine nucleoside phosphorylase [26]. PEG–ADA has been
successfully applied in the treatment of ADA deficiency
[2,3]. We present here the synthesis, characterization and
potential uses of PEG-conjugated AP.
The engineered AP coding sequence [1] was inserted into
the multiple cloning site of pET28a-c(+) (Novagen). The
resulting enzyme contains the additional 24 N-terminal
residues including a 6-histidine tag for purification by nickel
affinity chromatography. Recombinant homogeneous AP
was readily obtained by affinity chromatography.
Although substantial benefits and properties have been
achieved using 5 kDa PEG species, recent studies have
shown the successful application of branched 40 kDa PEG
molecules [27]. The branched PEG molecule has the poten-
tial to provide a larger protein masking effect with reduced
number of sites of attachments and less penetration into
potentially important structural domains. Thus, 40 kDa PEG
conjugated with interferon alpha 2a has reached clinical
trials [28–30]. PEG conjugation was carried out using the
N-hydroxysuccinimide ester of a branched methoxypoly-
ethylene glycol (mPEG2-NHS) of approximately 42.5 kDa
as specified by the supplier (Shearwater Polymers). The
electrophilic carbon of the N-hydroxysuccinimide ester is
the reactant species which conjugates with external lysine
residues of the target protein [27]. As the mPEG2-NHS
reagent is very labile under the reaction conditions, a range
of mPEG2-NHS and enzyme molar ratios between 10:1 and
160:1 were examined for optimal conjugation. The degree
of PEG-enzyme conjugate formation was monitored by
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SDS-PAGE electrophoresis and optimum conjugation oc-
curred with an approximate molar ratio of 100:1. Examina-
tion of the consequences of exposure to the reaction
conditions on the native enzyme alone showed a loss of
7% of activity. Retention of catalytic activity or biological
function is of significant importance in developing a PEG-
conjugated protein. The specific activity of the final PEG-
conjugated protein was approximately 90% that of the
native AP.
The PEG-conjugated enzyme was purified by FPLC on a
Superdex 200 exclusion column. SDS-PAGE analysis of the
purified recombinant protein and the PEG-conjugated prod-
uct revealed that the major PEG protein complex was
greater than 205 kDa (Fig. 1) having just entered the 8%
gel after passing through the 5% stacking gel. The findings
indicate a minimal molecular mass of not less than 205 kDa
which is consistent with the attachment of four of the 42.5-
kDa PEG species per 35 kDa AP monomer. MALDI
analysis (15) of the native and conjugated products revealed
the native material to be homogeneous having expected
mass ions corresponding to the monomer, dimer and trimer
(Fig. 2a). Analysis of the PEG-conjugated product showed
the expected 35-kDa monomer conjugated to n + 1, + 2, + 3
and + 4 of the 42.5-kDa PEG species (Fig. 2b). The spectra
of the conjugated species are broad, as the reactant 42.5-kDa
PEG reagent is a mixture with an unspecified range of
molecular mass.
3.2. Analysis of AP activity
As 2-chloro-2V-deoxyadenosine is refractory to deami-
nation via ADA [17,18] and has a velocity with AP equi-
valent to that of adenosine, we used this substrate to monitor
AP activity in plasma and tissue. Further we have shown that
2-chloro-2V-deoxyadenosine is not a substrate for recombi-
nant purine nucleoside phosphorylase. We were able to
demonstrate via reverse-phase HPLC that 2-chloroadenine
is a substrate for xanthine oxidase and the coupled reaction
was therefore employed as previously described [1], sub-
stituting 2-chloro-2V-deoxyadenosine for adenosine as sub-
strate.
3.3. In vivo turnover of native and PEG-conjugated AP in
the purine nucleoside phosphorylase-deficient mouse
Both the native and the PEG-conjugated AP were
administered intraperitoneally as a single bolus, 3.5 Ag/g
weight of mouse, to the B6-NPG purine nucleoside phos-
phorylase-deficient mice [13]. The PNP-deficient mice
provide a background essentially free of any purine nu-
cleoside cleavage potential having < 0.1% PNP activity
in liver. Intraperitoneal enzyme administration showed a
peak of plasma AP activity at 4 h for the native enzyme
Fig. 1. Synthesis of PEG–AP. Purified native and PEG–AP were examined
by SDS-PAGE with a 5% stacking and 8% running gel. Far left lane, Bio-
Rad prestained broad range MW markers (7.5 Al); lane 1, native AP (10
Ag); lane 2, PEG–AP (10 Ag).
Fig. 2. MALDI mass spectrometry analysis of AP and PEG–AP. The
recombinant AP is predicted to have a molecular mass of 34,979 Da. (A)
Native AP with peaks corresponding to f 35 kDa monomer, f 70 kDa
dimer, and f 105 kDa trimer. (B) PEG–AP shows broad peaks cor-
responding to an AP monomer plus 1–4, 42.5 kDa PEG species. The
width of the peaks is representative of the heterogeneity of the PEG
groups.
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(Fig. 3a) and at 8 h for the PEG-conjugated enzyme (Fig.
3b). Peak activities were 34 and 322 nmol/min/ml plasma
for the native and PEG–AP, respectively. Even though
equal units of enzyme activity were administered, the peak
activity for the native enzyme was approximately 10-fold
less than that for PEG-AP, suggesting greater degradation
or inactivation of native enzyme before accumulation in the
plasma.
The native AP activity declined at a relatively fast rate
and was essentially negligible by 10 h. The PEG-conju-
gated enzyme by contrast had a much longer resident time
in the plasma extending past 5 days. The half-lives deter-
mined from the pseudo-first-order decay in activity were
determined to be 57.8F 1.1 min for native AP (Fig. 4a)
and 65.1F 2.9 h for PEG–AP (Fig. 4b). Thus, the half-life
has been increased greater than 65-fold by masking the
enzyme with PEG. This marked in vivo difference was not
due to intrinsic differences in protein stability as in vitro
thermal inactivation studies revealed that the proteins had
comparable stability at 50 jC with half-lives of 79 and 52
min for the native and PEG-conjugated enzymes, respec-
tively.
Tissues and urine from the enzyme-treated mice were
examined for AP activity at various times (Table 1). At
those time points assessed, there was only minimal tissue
AP present, with spleen showing the greatest level of
activity. There was no evidence of AP activity in the urine
at any of the times monitored consistent with the limits of
renal exclusion. Consideration of the relative weight or
volume of tissues indicates that greater than 95% of the
activity is retained in the blood plasma. Thus, the turnover
may be considered due to degradation or loss of enzyme
activity, as there is minimal accumulation of activity in
tissues and essentially none in urine.
3.4. Consequence of PEG–AP on urate levels
Hypouricemia has been recognized as a metabolic and
diagnostic feature of purine nucleoside phosphorylase defi-
ciency [3,31]. Although AP has been engineered to have a
Fig. 4. Semi-log plot of relative AP plasma activity as a function of time.
The slope of the regression line was used to calculate the half-life of the
proteins. (A) Native AP. (B) PEG–AP.
Table 1
Tissue and physiological fluid AP activity for PEG–AP-treated mice
Tissue AP (nmol/min/g tissue)
Thymus < 0.17
Brain 0.17F 0.24
Lung 1.0F 1.5
Liver 3.4F 1.1
Kidney 5.5F 4.9
Spleen 6.7F 3.0
Fluid (nmol/min/ml)
Urine < 0.17
Plasma 113F 24
Tissues and plasma were prepared from three mice at 142 h following
administration of PEG–AP. Urine assayed from collections at 2, 5, 46, 94
and 154 h showed no detectable activity. Untreated control mice gave no
detectable tissue or fluid AP activity, < 0.17 nmol/min per gram tissue or
per milliliter fluid.
Fig. 3. Relative AP activity in mouse plasma following injection of native
AP or PEG–AP. Mice were injected with 3.5 Ag protein/g mouse and
plasma was obtained at the times indicated and assayed for AP activity.
Results are the meansF S.D. (n= 3 mice per point). (A) Plasma time course
of native AP. One hundred percent activity corresponds to 34 nmol product/
min/ml plasma. (B) Plasma time course of PEG–AP. One hundred percent
activity corresponds to 322 nmol product/min/ml plasma.
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comparative substrate specificity advantage for adenosine,
activity has been retained with the natural substrate inosine.
Thus, the Km for inosine has been markedly increased from
40 AM for native PNP to 840 AM for the engineered protein
[1]. The retained specific activity with inosine is, however,
substantial, approximately one fourth of the native enzyme.
As the purine nucleoside phosphorylase-deficient mice
accumulate the substrates of PNP in the urine [32] and
exhibit a partial reduction in the urate levels, we examined
the consequence of PEG–AP on the level of urate. The
PEG–AP-administered mice did not show a significant
reduction in nucleoside levels; however, there was evidence
of enhanced nucleoside cleavage as the urate levels were
increased 2.7-fold for voids between 22 and 58 h and 1.8-
fold between 94 and 154 h (Table 2). The amount of plasma
PEG-AP attained by a single injection may be rate limiting
for the conversion of inosine and guanosine toward urate in
comparison to the endogenous rate of accumulation of
inosine and guanosine in the PNP-deficient mouse. In
addition, urate is further metabolized in the mouse to
allantoin by uricase [33]; however, in the present study we
have only examined the consequence of PEG-AP on urine
urate levels. Overall, these findings demonstrate the in vivo
function of the PEG-conjugated AP by the increase in the
excretion of urate. The relative changes in urate levels of the
PEG-AP-treated mice correspond to the decline in the
measured plasma phosphorylase activity for these time
periods (Fig. 3).
3.5. Protection of CEM cells from deoxyadenosine toxicity
by AP
Deoxyadenosine, which accumulates in ADA deficiency,
is attributed to be the precursor, which effectively provokes
the events leading to the combined T- and B-cell immuno-
deficiency disease [2]. Human CEM cells cultured in the
presence of an ADA inhibitor are sensitive to 10 AM
deoxyadenosine (Fig. 5). Co-administration of AP to these
cultures restored the proliferation of CEM cells to near
normal levels and demonstrated the in vitro capability of
AP to protect against the toxic effects of deoxyadenosine.
This is accomplished in part due to the relatively inert
properties of the reaction product, adenine, which can be
tolerated at near millimolar levels by cells in culture [22].
By conversion of deoxyadenosine to adenine, PEG-AP is
proposed to protect the CEM lymphoblasts from the accu-
mulation of dATP.
4. Overview
Overall, these studies have demonstrated the feasibility
of producing a PEG-conjugated AP which has retained
essentially normal levels of catalytic activity. Evidence
was obtained for the enzyme to be conjugated to as many
as four branched 42 kDa PEG adducts per monomer. The
protected enzyme exhibited a marked 67-fold increase in
plasma half-life in the mouse as compared to the native
enzyme and attained a 9.5-fold greater maximal activity in
the plasma. PEG–AP activity was principally confined to
the plasma as anticipated. The consequences of repeated
injections of PEG-AP on attainable plasma activity and
immunogenicity of the PEG–AP complex remain to be
examined. The engineered AP, which also has activity
with inosine, was shown to result in increased urate levels
when administered to the PNP-deficient mouse thereby
demonstrating in vivo function. The enzyme was also
shown to be capable of protecting CEM cells from
deoxyadenosine toxicity in culture. These findings lend
support to the view that the engineered AP has potential
as an alternate form of enzyme therapy in ADA defi-
ciency as well as in the activation of nucleoside analog
prodrugs via their conversion to their respective purine
base analog.
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Fig. 5. Protection of human CEM cells from 2V-deoxyadenosine toxicity by
AP. CEM cells were grown in culture in the presence of the ADA inhibitor
EHNA, 5 AM, and the presence or absence of 10 AM 2V-deoxyadenosine
with or without AP, 5 Ag/ml.
Table 2
Urine urate level in B6-NPG purine nucleoside phosphorylase-deficient
mice and PEG–AP-administered mice
PEG–AP treatment Uric acid (AM)
B6-NPG, untreated 830F 314 (n= 6)
B6-NPG plus PEG–AP, 22–70 h 2163F 832 (n= 4)
B6-NPG plus PEG–AP, 94–154 h 1506F 310 (n= 4)
Results are the meansF S.D. for the number of pooled urines taken during
the intervals specified. The results are significantly different from one
another, PV 0.001; a= 0.05.
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